Answers are grounded in this paper and cite their sources.
Background Treatment options for refractory cancer therapy-induced thrombocytopenia (R-CTIT) are limited. This real-world retrospective cohort study evaluated the effectiveness and safety of fixed-dose romiplostim in patients with R-CTIT. Methods In this retrospective analysis, 28 patients with R-CTIT received romiplostim (250 μg/week) at our center (2023–2024). Outcomes included time to response, platelet increase, bleeding score, transfusion independence, and safety. Results Median time to platelet response was 7 days. By week 3, platelet counts rose from 19 × 10 9 /L to 136 × 10 9 /L ( P < 0.001), with an objective response rate (ORR) of 92.9% (26/28; 75% complete response). At week 8, responses were sustained (ORR 92.9%; platelets 108 × 10 9 /L, P < 0.001). Bleeding scores improved; 93.3% achieved platelet transfusion independence. Hemoglobin increased (90 g/L to 112 g/L, P = 0.029), with a trend toward higher neutrophils. Twenty responders resumed anticancer therapy. After romiplostim discontinuation (n = 7), 71.4% experienced recurrent grade IV thrombocytopenia. Three patients (10.7%) developed deep vein thrombosis. Conclusion Fixed-dose romiplostim (250 μg/week) induces rapid and durable platelet responses, improves bleeding and hematologic parameters, and facilitates continued anticancer therapy in R-CTIT in this real-world retrospective cohort. Thrombocytopenia commonly recurs after stopping, and thrombotic risk warrants monitoring. Prospective studies with larger samples and a control group are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: